Dax

DGAP-News: BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed

Retrieved on: 
Venerdì, Gennaio 21, 2022 - 7:02am

Media release as at January 21, 2022

Key Points: 
  • Media release as at January 21, 2022
    Portfolio of BB Biotech AG as at December 31, 2021
    The year 2021 was a volatile market environment for all involved in biotechnology investing, including BB Biotech.
  • BB Biotech carefully adjusted the portfolio in the last three months of 2021.
  • The net loss for BB Biotech in 2021 was CHF 405 mn.
  • The highly specialized investment team at BB Biotech believes that the growth case for biotechnology and valuations for portfolio companies are both compelling.

Daxbot Announces First Funding Round

Retrieved on: 
Venerdì, Settembre 17, 2021 - 6:00pm

PHILOMATH, Ore., Sept. 17, 2021 /PRNewswire/ -- Today, Daxbot, Inc. announced the launch of their Regulation Crowdfunding raise.

Key Points: 
  • PHILOMATH, Ore., Sept. 17, 2021 /PRNewswire/ -- Today, Daxbot, Inc. announced the launch of their Regulation Crowdfunding raise.
  • Daxbot has several robot deployments scheduled this year in different cities across the United States.
  • The goal of the funding round is to increase the number of robots and be able to have delivery robots in 10 key cities across the United States in 2022.
  • To learn more about the Daxbot funding round, please visit: https://www.startengine.com/daxbot
    Daxbot's mission is to put robots in the service of humanity.

DGAP-News: Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps

Retrieved on: 
Venerdì, Luglio 23, 2021 - 7:00am

BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021.

Key Points: 
  • BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021.
  • Major regulatory decisions for several companies in BB Biotech's portfolio are also expected in the second half of the year.
  • BB Biotech's share price was 5.8% in CHF and 6.1% in EUR during the second quarter 2021.
  • The quarterly report of BB Biotech AG as at June 30, 2021 can be downloaded at report.bbbiotech.ch/Q221 or www.bbbiotech.com

DGAP-News: BB BIOTECH AG: Successful vaccination campaigns point the way out of the corona crisis - sector re-valuation used for portfolio investments

Retrieved on: 
Venerdì, Aprile 23, 2021 - 10:49pm

Its stock ended the quarter with a positive total return of 15.4% in CHF and 14.3% in EUR.

Key Points: 
  • Its stock ended the quarter with a positive total return of 15.4% in CHF and 14.3% in EUR.
  • Countries such as Israel, the US and the UK that secured early access to vaccines have experienced sharp drops in infection and hospitalization rates.
  • Although most other countries are making slower progress with their vaccination campaigns, they are likely to eventually show similar developments.
  • This should have a variety of positive effects on companies in the biotech sector.

INTERSECT BY LEXUS-NYC To Welcome Three Michelin Star Restaurant, Manresa, As Next Restaurant-In-Residence And Launch New Outdoor Dining Area

Retrieved on: 
Mercoledì, Aprile 14, 2021 - 3:00pm

"We look forward to flexing our creativity and presenting tasting and la carte menus reflective of our Manresa fine dining experience at INTERSECT BY LEXUS.

Key Points: 
  • "We look forward to flexing our creativity and presenting tasting and la carte menus reflective of our Manresa fine dining experience at INTERSECT BY LEXUS.
  • The design concept translates Lexus\' ethosinspired design, relentless innovation, and exceptional experiencesinto a flexible, modular sidewalk seating area featuring a streamlined L-framed dining pavilion.
  • Opened in New York City on November 15, 2018, guests are able to engage with Lexus through food and culture.
  • A destination within a destination, INTERSECT offers a Restaurants-in-Residence program, allowing New Yorkers and world travelers to consistently embark upon a new gastronomic adventure.\n'

DGAP-News: BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed

Retrieved on: 
Venerdì, Gennaio 22, 2021 - 7:00am

The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies.

Key Points: 
  • The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies.
  • BB Biotech exited four holdings and added three new holdings in the last three months of 2020.
  • The net gain for BB Biotech in 2020 was CHF 691 mn.
  • Weakening of the USD versus the CHF and EUR throughout the year created additional headwind for CHF and Euro-denominated performance.